28 completed, 19 unknown, 11 terminated, 6 recruiting. 70 Phase 2, 12 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 70 | Completed 28, Unknown 19, Terminated 11, Recruiting 6, Withdrawn 3, Not yet recruiting 2, Active not recruiting 1 |
| Phase 1 | 12 | Completed 3, Recruiting 3, Terminated 3, Unknown 3 |
Follow Non-Small-Cell Lung Cancer: new trials by email Literature Review of Non-Small-Cell Lung Cancer trials Research Report on Non-Small-Cell Lung Cancer
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Vebreltinib Plus Furmonertinib in Patients With EGFR-mutated Advanced Non-small Cell Lung Cancer and High PD-L1 Expression Vebreltinib, Furmonertinib 80mg - Non-Small-Cell Lung Cancer | Phase 1 / Phase 2 | Recruiting | Second Affiliated Hospital of Nanchang University | 45 | 2026-07-03 | 2026-06-18 |
| Andamertinib With or Without Platinum-doublet Chemotherapy Versus Platinum-doublet Chemotherapy in Patients With NSCLC Harboring Atypical EGFR Mutations PLB1004 - Non-Small-Cell Lung Cancer | Phase 2 | Recruiting | Avistone Biotechnology Co., Ltd. | 40 | 2026-03-11 | 2026-03-20 |
| Combination of Vebreltinib and Osimertinib in Patients with EGFR 21 L858R Mutation Advanced NSCLC Vebreltinib, Osimertinib - Non-Small-Cell Lung Cancer | Phase 2 | Active not recruiting | National Cancer Center, China | 30 | 2024-10-14 | 2025-02-14 |
| Vebreltinib Plus PLB1004 as the First-line Therapy for Patients With EGFRm+/MET+ Locally Advanced or Metastatic NSCLC. Vebreltinib, Osimertinib, PLB1004 - Non-Small-Cell Lung Cancer | Phase 2 | Recruiting | Avistone Biotechnology Co., Ltd. | 120 | 2024-08-07 | 2025-05-21 |
| A Study of SBRT Combined With Puterizumab in Intrapulmonary Metastasis From NSCLC Stereotactic Body Radiation Therapy，SBRT, Puterizumab - Non-Small-Cell Lung Cancer | Phase 2 | Not yet recruiting | Sir Run Run Shaw Hospital | 37 | 2024-06-01 | 2024-05-30 |
| Golidocitinib in Combination With Sintilimab for PD-L1 Selected Treatment Locally Advanced or Metastatic Non-Small Cell Lung Cancer(NSCLC) Golidocitinib, Sintilimab, platinum doublet chemotherapy - Non-Small-Cell Lung Cancer | Phase 2 | Not yet recruiting | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 69 | 2024-01-01 | 2024-01-10 |
| Efficacy and Safety of HL-085 Combined With Vemurafenib in BRAF V600E Patients With Non-small Cell Lung Cancer: a Phase II Clinical Study HL-085+Vemurafenib - Non-small-cell Lung Cancer | Phase 2 | Unknown | Shanghai Kechow Pharma, Inc. | 75 | 2023-09-24 | 2023-06-12 |
| Vebreltinib Plus PLB1004 in EGFR-mutated, Advanced NSCLC With MET Amplification or MET Overexpression Following EGFR-TKI Vebreltinib, PLB1004 - Non-Small-Cell Lung Cancer | Phase 1 / Phase 2 | Recruiting | Avistone Biotechnology Co., Ltd. | 156 | 2023-06-13 | 2025-05-21 |
| Phase II Clinical Trial to Evaluate the Safety and Efficacy of TQB2450 Injection Combined With Anlotinib Capsule and Chemotherapy in the Treatment of Immunoresistant Advanced Non-small Cell Lung Cancer TQB2450 +Anlotinib+Docetaxel, TQB2450 +Androtinib Placebo+Docetaxel - Non-small-cell Lung Cancer | Phase 2 | Recruiting | Tianjin Medical University Cancer Institute and Hospital | 148 | 2023-04-12 | 2024-09-19 |
| A Study of QL1706 Combined With Chemotherapy in Advanced Non-small Cell Lung Cancer QL1706 - Non-small-cell Lung Cancer | Phase 2 | Unknown | Qilu Pharmaceutical Co., Ltd. | 100 | 2022-06-01 | 2023-11-24 |
| Efficacy and Safety of Furmonertinib in EGFR-Mutant, PD-L1+ Patients With Locally Advanced or Metastatic NSCLC (FUTURE) Furmonertinib (160mg) - Non-Small-Cell Lung Cancer | Phase 2 | Unknown | Fudan University | 62 | 2021-12-09 | 2022-08-04 |
| Furmonertinib Combined With Anlotinib as the First-line Treatment in Patients With EGFR Mutation-positive NSCLC Furmonertinib, Anlotinib - Non-Small-Cell Lung Cancer | Phase 2 | Unknown | Shanghai Chest Hospital | 40 | 2021-10-12 | 2023-01-06 |
| A Study of BMS-986340 as Monotherapy and as Combination Therapy in Participants With Advanced Solid Tumors BMS-986340, BMS-936558-01, Docetaxel - Cervical Cancer, Gastric/Gastroesophageal Junction Adenocarcinoma | Phase 1 / Phase 2 | Recruiting | Bristol-Myers Squibb | 1109 | 2021-05-27 | 2026-08-17 |
| CAB-AXL-ADC Safety and Efficacy Study in Adults With NSCLC CAB-AXL-ADC, PD-1 inhibitor - Non-Small-Cell Lung Cancer | Phase 2 | Completed | BioAtla, Inc. | 85 | 2021-03-17 | 2025-09-25 |
| First-Line Treatment of Advanced Non-Small-Cell Lung Cancer With Negative Driver Gene: a Multicenter, Single-Arm Trial Recombinant human endostatin (Endostar) - Non-Small-Cell Lung Cancer | Phase 2 | Unknown | Qianfoshan Hospital | 100 | 2021-02-01 | 2022-10-12 |
| A Trial of SHR-1701 With or Without Famitinib in Patients With Advanced or Metastatic NSCLC SHR-1701，Famitinib, SHR-1701 - Non-Small-Cell Lung Cancer | Phase 2 | Withdrawn | Jiangsu HengRui Medicine Co., Ltd. | 2021-01-15 | 2023-06-07 | |
| A Trial of SHR-1701 With or Without Chemotherapy in Patients With Stage III NSCLC SHR-1701+Paclitaxel+carboplatin, SHR-1701 - Non-Small-Cell Lung Cancer | Phase 2 | Unknown | Jiangsu HengRui Medicine Co., Ltd. | 107 | 2020-11-10 | 2023-05-19 |
| A Trial of SHR1701 Combined With Radiotherapy for Metastatic Non-small Cell Lung Cancer Failure After First-line Treatment SHR1701 - Non-Small-Cell Lung Cancer | Phase 2 | Unknown | Shandong Cancer Hospital and Institute | 15 | 2020-09-01 | 2020-09-23 |
| Pyrotinib Plus Thalidomide in Advanced NSCLC Patients Harboring HER2 Exon 20 Insertions pyrotinib combined with thalidomide - Non-small-cell Lung Cancer | Phase 2 | Unknown | Shanghai Chest Hospital | 39 | 2020-06-30 | 2021-01-28 |
| Sintilimab (IBI308) in the Neoadjuvant Treatment of Patients With Resectable II-IIIA NSCLC Sintilimab injection - Lung Diseases, Neoplasms | Phase 2 | Unknown | Sichuan Cancer Hospital and Research Institute | 20 | 2020-05-10 | 2020-05-01 |
Showing 20 of 70. Sign in to see all of them.
Carcinoma, Non-Small-Cell Lung (70) · Lung Neoplasms (9) · Neoplasms (8) · Adenocarcinoma (3) · Adenocarcinoma of Lung (3) · Carcinoma, Renal Cell (2) · Carcinoma, Squamous Cell (2) · Lung Diseases (2) · Melanoma (2) · Neoplasm Metastasis (2) · Respiratory Tract Diseases (2) · Thoracic Neoplasms (2) · Brain Neoplasms (1) · Breast Neoplasms (1) · Carcinoma (1)
Bronchial Neoplasms (70) · Carcinoma, Bronchogenic (70) · Neoplasms by Site (70) · Respiratory Tract Neoplasms (70) · Lung Diseases (68) · Respiratory Tract Diseases (68) · Thoracic Neoplasms (68) · Neoplasms (62) · Lung Neoplasms (61) · Neoplasms by Histologic Type (9) · Neoplasms, Glandular and Epithelial (8) · Carcinoma (7) · Adenocarcinoma (5) · Skin Diseases (4) · Skin and Connective Tissue Diseases (4)
Pemetrexed (14) · Cisplatin (9) · Carboplatin (7) · Docetaxel (7) · Erlotinib Hydrochloride (5) · Bevacizumab (4) · Gefitinib (3) · Gemcitabine (3) · Paclitaxel (3) · SHR-1701 (3) · aflutinib (3) · apatinib (3) · Cetuximab (2) · Drug Therapy (2) · Nivolumab (2)
Eli Lilly and Company (8) · Hellenic Oncology Research Group (4) · Novartis Pharmaceuticals (4) · Avistone Biotechnology Co., Ltd. (3) · Jiangsu HengRui Medicine Co., Ltd. (3) · Betta Pharmaceuticals Co., Ltd. (2) · Bristol-Myers Squibb (2) · Fudan University (2) · GlaxoSmithKline (2) · Qilu Pharmaceutical Co., Ltd. (2) · Shandong Cancer Hospital and Institute (2) · Shanghai Chest Hospital (2) · Sichuan Cancer Hospital and Research Institute (2) · Sun Yat-sen University (2) · AbbVie (prior sponsor, Abbott) (1)
China (31) · United States (20) · Greece (7) · Canada (5) · Germany (5) · Japan (5) · Spain (5) · Italy (4) · Taiwan (4) · India (3) · Netherlands (3) · Poland (3) · Russia (3) · South Korea (3) · Ukraine (3)
Juan Li, MD (2) · Manolis Kontopodis, MD (2) · Sofia Agelaki, MD (2) · Anthony Brade, MD (1) · Anwen Liu, PhD (1) · Athanasios Karampeazis, MD (1) · Caicun Zhou (1) · Caicun Zhou, MD,PhD (1) · David R Spigel, MD (1)
PMID 16012180, PMID 16807466, PMID 19692680, PMID 21108883, PMID 21300929, PMID 22461641, PMID 23332288, PMID 23350714, PMID 23890768, PMID 24668644, PMID 25028118, PMID 25747273, PMID 26228759, PMID 26871284, PMID 27843623, PMID 29247830, PMID 29959809, PMID 30773184, PMID 30785829, PMID 34530760, PMID 37348348, PMID 38282003, PMID 38700579, PMID 39281971, PMID 42303632
2004 (1), 2023 (1), P01CA021239 (1)